Empagliflozin Beneficial in Type 1 Diabetes, DKA a Risk
The sodium-glucose cotransporter type 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) improved glycemic control and weight in type 1 diabetes, but also increased the risk for diabetic ketoacidosis (DKA), new data show. Findings from the Empagliflozin as Adjunctive to Insulin Therapy (EASE) program were presented October 4 here at
Continua a leggere